Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Japanese study of epcoritamab in B-cell non-Hodgkin lymphoma
jRCT2080225312Phase 2Completed
- Sponsor
- Genmab
- Start
- Aug 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 4 more (5 arms), sponsored by Genmab. Started Aug 2020; status: completed.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCT2080225312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225312.